Objective
MMalignant diseases represent a major health problem in all parts of the world and their incidence, according to the WHO/
IARC World Cancer Report 2014, will increase by 57% worldwide in the next 20 years. Standard treatment strategies for
cancer including surgery, chemotherapy and targeted molecular therapy still do not guarantee complete elimination of the
disease. In addition, cancer cells exhibited high capability to escape from immunosurveillance after applied treatment which
was confirmed with frequently occurred relapse of disease.
BIRD-C have developed Bacterial Ghost Cancer Immunotherapy (BGCI) - a novel personalised medicine approach towards
vaccination against tumours. BIRD-C’s therapeutic cancer vaccines are based on personalised dendritic cells-based cancer
immunotherapy that targets the tumour microenvironment using Bacterial Ghosts (BGs), the proprietary platform technology
of BIRD-C. The tumour therapy strategy is to (re)stimulate the patient immune system to revert the tumour evasion and build
strong humoral and cellular immune responses against patient-specific tumour antigens. Obtained results show that BGCI
can generate effective response to tumours and indicate novel prospective methods for cellular cancer immunotherapy. This
approach has been tested in a form of advanced personalised cancer therapy and has improved the survival of patients with
solid tumours.
During the project, BIRD-C will develop the manufacturing procedure and commercial scale-up strategy and also conduct a
multi-centre trial with patients affected by various forms of cancer at different stages of progression to determine the
tolerability and effectiveness of the treatment.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine oncology
- medical and health sciences health sciences personalized medicine
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3420 KRITZENDORF
Austria
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.